The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A phase 1b study in cutaneous T-cell lymphoma (CTCL) with the novel topically applied skin-restricted histone deacteylase inhibitor (HDAC-i) SHP-141.
Youn H. Kim
No relevant relationships to disclose
Michael Krathen
No relevant relationships to disclose
Madeleine Duvic
No relevant relationships to disclose
Henry Wong
No relevant relationships to disclose
Pierluigi Porcu
No relevant relationships to disclose
Joselin Tacastacas
No relevant relationships to disclose
Neil J Korman
No relevant relationships to disclose
Joan Guitart
No relevant relationships to disclose
James E. Bradner
Employment or Leadership Position - Shape Pharmaceuticals
Consultant or Advisory Role - Shape Pharmaceuticals
Stock Ownership - Shape Pharmaceuticals
Steven B. Landau
Employment or Leadership Position - Healthcare Ventures; Shape Pharmaceuticals
Stock Ownership - Shape Pharmaceuticals